Pfizer receives clearance to acquire Hospira
The FTA terminated the waiting period that is typically required under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, but approval is dependent on Pfizer divesting itself of four U.S. sterile injectable assets, including Acetylcysteine, Clindamycin, Voriconazole and Melphalan.
In conjunction, the Superintendency-General of the Council for Economic Defense (CADE) in Brazil released its unconditional clearance decision concerning the acquisition as well.
“We are pleased to have received these final regulatory approvals for our pending acquisition of Hospira,” Ian Read, chairman and CEO of Pfizer, said. “We now look forward to combining our two companies and expect the transaction to close in early September.”
Pfizer is known for using science as well as worldwide resources to provide people with therapies that extend and improve their quality of life.
Based in Lake Forest, Illinois, Hospira manufactures generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management systems.